Answers are grounded in this paper and cite their sources.
Dynamic factor analysis identifies key biomarkers, including the kynurenine pathway, in sparse longitudinal data from a COVID-19 study, suggesting clinical implications.
Factor analysis (FA) can be used to identify key biomarkers in biological processes by assuming that latent biological pathways (statistically, `latent factors') drive the activity of measurable biomarkers (`observed variables'). However, biological pathways often interact, meaning that the classical FA assumption of independence between factors is questionable. Motivated by sparsely and irregularly collected longitudinal measurements of metabolites in a COVID-19 study, we propose a dynamic factor analysis model that accounts for cross-correlations between pathways via a multi-output Gaussian processes (MOGP) prior on the factor trajectories. To mitigate against overfitting caused by sparsity of longitudinal measurements, we introduce a roughness penalty upon MOGP hyperparameters and allow for non-zero mean functions. We also propose a scalable stochastic expectation maximization (StEM) algorithm that, in simulations, is both 20 times faster and provides more accurate and stable MOGP hyperparameter estimates than a previously-proposed Monte Carlo Expectation Maximisation algorithm. In the motivating COVID-19 study, our methodology identifies a kynurenine pathway that affects the clinical severity of patients with COVID-19 disease and uncovers the role of the biomarker taurine. Our R package DFA4SIL implements the proposed method.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: